Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Johnson and Johnson
Baxter
Colorcon
AstraZeneca

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Zicronapine

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Zicronapine?

Zicronapine is an investigational drug.

There have been 4 clinical trials for Zicronapine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2011.

The most common disease conditions in clinical trials are Schizophrenia and [disabled in preview]. The leading clinical trial sponsors are H. Lundbeck A/S and [disabled in preview].

There are fourteen US patents protecting this investigational drug and two hundred and forty-four international patents.

Recent Clinical Trials for Zicronapine
TitleSponsorPhase
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With SchizophreniaH. Lundbeck A/SPhase 2
Safety and Efficacy of Zicronapine in Patients With SchizophreniaH. Lundbeck A/SPhase 3
Efficacy of Lu 31-130 in Patients With SchizophreniaH. Lundbeck A/SPhase 2

See all Zicronapine clinical trials

Clinical Trial Summary for Zicronapine

Top disease conditions for Zicronapine
Top clinical trial sponsors for Zicronapine

See all Zicronapine clinical trials

US Patents for Zicronapine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Zicronapine   Start Trial Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia H. LUNDBECK A/S (Valby, DK)   Start Trial
Zicronapine   Start Trial Crystalline base of trans-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine H. Lundbeck A/S (Valby-Copenhagen, DK)   Start Trial
Zicronapine   Start Trial Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament H. Lundbeck A/S (Valby-Copenhagen, DK)   Start Trial
Zicronapine   Start Trial Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine H. Lundbeck A/S (Valby-Copenhagen, DK)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Zicronapine

Drugname Country Document Number Estimated Expiration Related US Patent
Zicronapine African Regional IP Organization (ARIPO) 3310 2031-06-20   Start Trial
Zicronapine Argentina 086987 2031-06-20   Start Trial
Zicronapine Australia 2012273657 2031-06-20   Start Trial
Zicronapine Brazil 112013031702 2031-06-20   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
Colorcon
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.